Humanized mice recapitulate key features of HIV-1 infection: A novel concept using long-acting anti-retroviral drugs for treating HIV-1

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Nischang, Marc ^a   Sutmuller, Roger ^b   Gers Huber, Gustavo ^a   Audigé, Annette ^a   Li, Duo ^a   Rochat, Mary Aude ^a   Baenziger, Stefan ^a   Hofer, Ursula ^a   Schlaepfer, Erika ^a   Regenass, Stephan ^a   Amssoms, Katie ^b   Stoops, Bart ^b   van Cauwenberge, Anja ^b   Boden, Daniel ^b   Kraus, Guenter ^b   Speck, Roberto F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b TIBOTEC BVBA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; LONG ACTING DRUG; PROTEINASE INHIBITOR; RILPIVIRINE; RITONAVIR; TENOFOVIR DISOPROXIL; TMC 181; UNCLASSIFIED DRUG; VIRUS DNA; ZIDOVUDINE;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL RESISTANCE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; MONOTHERAPY; MOUSE; NEWBORN; NONHUMAN; REBOUND; VIRUS CARRIER; VIRUS LOAD; VIRUS MUTATION; VIRUS REACTIVATION; WASTING SYNDROME; WEIGHT REDUCTION;

ANIMALS; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; RNA, VIRAL; VIRAL LOAD;

EID: 84862224258     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038853     Document Type: Article

References (43)

1. Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, et al. (2006) The survival benefits of AIDS treatment in the United States. J Infect Dis 194: 11-19.
2. Heeney JL, Dalgleish AG, Weiss RA, (2006) Origins of HIV and the evolution of resistance to AIDS. Science 313: 462-466.
3. McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, et al. (1988) The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 241: 1632-1639.
4. Namikawa R, Kaneshima H, Lieberman M, Weissman IL, McCune JM, (1988) Infection of the SCID-hu mouse by HIV-1. Science 242: 1684-1686.
5. Bonyhadi ML, Kaneshima H, (1997) The SCID-hu mouse: an in vivo model for HIV-1 infection in humans. Mol Med Today 3: 246-253.
6. Traggiai E, Chicha L, Mazzucchelli L, Bronz L, Piffaretti JC, et al. (2004) Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 304: 104-107.
7. Jiang Q, Zhang L, Wang R, Jeffrey J, Washburn ML, et al. (2008) FoxP3+CD4+ regulatory T cells play an important role in acute HIV-1 infection in humanized Rag2-/-gammaC-/- mice in vivo. Blood 112: 2858-2868.
8. Shultz LD, Ishikawa F, Greiner DL, (2007) Humanized mice in translational biomedical research. Nat Rev Immunol 7: 118-130.
9. Baenziger S, Tussiwand R, Schlaepfer E, Mazzucchelli L, Heikenwalder M, et al. (2006) Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-gamma c-/- mice. Proc Natl Acad Sci U S A 103: 15951-15956.
10. Berges BK, Wheat WH, Palmer BE, Connick E, Akkina R, (2006) HIV-1 infection and CD4 T cell depletion in the humanized Rag2-/-gamma c-/- (RAG-hu) mouse model. Retrovirology 3: 76.
11. Watanabe S, Terashima K, Ohta S, Horibata S, Yajima M, et al. (2007) Hematopoietic stem cell-engrafted NOD/SCID/IL2Rgamma null mice develop human lymphoid systems and induce long-lasting HIV-1 infection with specific humoral immune responses. Blood 109: 212-218.
12. Zhang L, Kovalev GI, Su L, (2007) HIV-1 infection and pathogenesis in a novel humanized mouse model. Blood 109: 2978-2981.
13. Gorantla S, Sneller H, Walters L, Sharp JG, Pirruccello SJ, et al. (2007) Human immunodeficiency virus type 1 pathobiology studied in humanized BALB/c-Rag2-/-gammac-/- mice. J Virol 81: 2700-2712.
14. Sango K, Joseph A, Patel M, Osiecki K, Dutta M, et al. (2010) Highly active antiretroviral therapy potently suppresses HIV infection in humanized Rag2-/-gammac-/- mice. AIDS Res Hum Retroviruses 26: 735-746.
15. Choudhary SK, Rezk NL, Ince WL, Cheema M, Zhang L, et al. (2009) Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-{gamma}c-/- mouse. J Virol 83: 8254-8258.
16. Choudhary SK, Archin NM, Cheema M, Dahl NP, Garcia JV, et al. (2012) Latent HIV-1 infection of resting CD4 T cells in the humanized Rag2/ gammac/ mouse. J Virol 86: 114-120.
17. Denton PW, Olesen R, Choudhary SK, Archin NM, Wahl A, et al. (2012) Generation of HIV latency in humanized BLT mice. J Virol 86: 630-634.
18. Marsden MD, Kovochich M, Suree N, Shimizu S, Mehta R, et al. (2012) HIV latency in the humanized BLT mouse. J Virol 86: 339-347.
19. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, et al. (2002) NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100: 3175-3182.
20. Watanabe S, Ohta S, Yajima M, Terashima K, Ito M, et al. (2007) Humanized NOD/SCID/IL2Rgamma(null) mice transplanted with hematopoietic stem cells under nonmyeloablative conditions show prolonged life spans and allow detailed analysis of human immunodeficiency virus type 1 pathogenesis. J Virol 81: 13259-13264.
21. Reagan-Shaw S, Nihal M, Ahmad N, (2008) Dose translation from animal to human studies revisited. FASEB J 22: 659-661.
22. Schrijvers R, Desimmie BA, Debyser Z, (2011) Rilpivirine: a step forward in tailored HIV treatment. Lancet 378: 201-203.
23. Vandamme AM, Camacho RJ, Ceccherini-Silberstein F, de Luca A, Palmisano L, et al. (2011) European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev 13: 77-108.
24. Goldstein H, Pettoello-Mantovani M, Katopodis NF, Kim A, Yurasov S, et al. (1996) SCID-hu mice: a model for studying disseminated HIV infection. Semin Immunol 8: 223-231.
25. Stoddart CA, Bales CA, Bare JC, Chkhenkeli G, Galkina SA, et al. (2007) Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals. PLoS ONE 2: e655.
26. Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentre F, et al. (2010) Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action. Clin Pharmacokinet 49: 17-45.
27. Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, et al. (2011) Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 378: 229-237.
28. Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, et al. (2011) Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 378: 238-246.
29. Chun TW, Justement JS, Moir S, Hallahan CW, Maenza J, et al. (2007) Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis 195: 1762-1764.
30. Baert L, van't Klooster G, Dries W, Francois M, Wouters A, et al. (2009) Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur J Pharm Biopharm 72: 502-508.
31. van't Klooster G, Hoeben E, Borghys H, Looszova A, Bouche MP, et al. (2010) Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob Agents Chemother 54: 2042-2050.
32. Miller CD, Crain J, Tran B, Patel N, (2011) Rilpivirine: a new addition to the anti-HIV-1 armamentarium. Drugs Today (Barc) 47: 5-15.
33. Camacho R, Teofilo E, (2011) Antiretroviral therapy in treatment-naive patients with HIV infection. Curr Opin HIV AIDS 6: S3-S11.
34. Taylor S, Boffito M, Khoo S, Smit E, Back D, (2007) Stopping antiretroviral therapy. AIDS 21: 1673-1682.
35. Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, et al. (2008) Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS 22: 2279-2289.
36. Cordery DV, Hesse K, Amin J, Cooper DA, (2010) Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients. Antivir Ther 15: 1035-1038.
37. Kaiser P, Joos B, Niederost B, Weber R, Gunthard HF, et al. (2007) Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes. J Virol 81: 9693-9706.
38. Althaus CF, Gianella S, Rieder P, von Wyl V, Kouyos RD, et al. (2010) Rational design of HIV-1 fluorescent hydrolysis probes considering phylogenetic variation and probe performance. J Virol Methods 165: 151-160.
39. Christopherson C, Kidane Y, Conway B, Krowka J, Sheppard H, et al. (2000) PCR-Based assay to quantify human immunodeficiency virus type 1 DNA in peripheral blood mononuclear cells. JClinMicrobiol 38: 630-634.
40. Manrique A, Rusert P, Joos B, Fischer M, Kuster H, et al. (2007) In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J Virol 81: 8793-8808.
41. T. Pattery YV, H. De Wolf, D Nauwelaers, K. Van Baelen, M. Van Houtte, P. Mc Kenna, J Villacian, (2012) Development and Performance of Conventional HIV-1 Phenotyping (Antivirogram) and Genotype-Based Calculated Phenotyping Assay (virco TYPE HIV-1) on Protease and Reverse Transcriptase Genes to Evaluate Drug Resistance. Intervirology pp. 138-146.
42. Fletcher CV, Kawle SP, Kakuda TN, Anderson PL, Weller D, et al. (2000) Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS 14: 2137-2144.
43. Chittick GE, Zong J, Blum MR, Sorbel JJ, Begley JA, et al. (2006) Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state. Antimicrob Agents Chemother 50: 1304-1310.